A key ambition of BenevolentAI is to utilize artificial intelligence in revolutionizing the drug development process. Now, with a licensing agreement with Janssen, it is one significant step closer to realizing that dream. With assistance from Johnson & Johnson Innovation's Centre in London, the British AI company has acquired an undisclosed number of novel clinical stage drug candidates, together with their related patents. The company used its AI platform to evaluate the potential of these small molecule compounds and found some could be promising candidates for hard-to-treat diseases. "The compounds come with a wealth of clinical and biological data that enables BenevolentAI to have further insights into the biology of diseases," said BenevolentAI Bio's CEO Jackie Hunter.